Cubuk, Mehmet Ozgur, Ucgul, Ahmet Yucel, Ozgur, Armagan, Ozulken, Kemal, Yuksel, ErdemCubuk M.O., Ucgul A.Y., Ozgur A., Ozulken K., Yuksel E.Cubuk, MO, Ucgul, AY, Ozgur, A, Ozulken, K, Yuksel, E2023-05-092023-05-092021-04-012021-04-012021.01.010165-5701https://hdl.handle.net/20.500.12597/12519To evaluate the clinical effect of topical cyclosporine A (CsA) (0.05%) on dry eye patients with Sjogren's syndrome (SS) and non-Sjogren's syndrome (NSS).This retrospective comparative study includes the dry eye (DE) patients who were treated with topical CsA. DE patients were divided into two groups as follows: DE with Sjogren's syndrome (DE-SS) and DE with Non-Sjogren's syndrome (DE-NSS). Dry eye parameters were recorded at baseline and each visit.Schirmer's test 1 scores were 2.7 ± 0.5 mm at baseline and 3.5 ± 0.7 mm at 12th month in DE-SS, 2.9 ± 0.7 mm at baseline and 9.5 ± 0.7 mm in DE-NSS groups at 12th month. Mean ST score was higher in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (both p = 0.001). Tear break-up time score showed a significant improvement in DE-NSS group, and it was lower in DE-NSS group than DE-SS group group at sixth and 12th months of the treatment (p = 0.044 and 0.027, respectively). Mean OSDI score was lower in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (p = 0.030 and 0.032, respectively).Topical CsA seems to be more effective in the treatment of the DE-NSS.Purpose: To evaluate the clinical effect of topical cyclosporine A (CsA) (0.05%) on dry eye patients with Sjogren’s syndrome (SS) and non-Sjogren’s syndrome (NSS). Method: This retrospective comparative study includes the dry eye (DE) patients who were treated with topical CsA. DE patients were divided into two groups as follows: DE with Sjogren’s syndrome (DE-SS) and DE with Non-Sjogren’s syndrome (DE-NSS). Dry eye parameters were recorded at baseline and each visit. Results: Schirmer’s test 1 scores were 2.7 ± 0.5 mm at baseline and 3.5 ± 0.7 mm at 12th month in DE-SS, 2.9 ± 0.7 mm at baseline and 9.5 ± 0.7 mm in DE-NSS groups at 12th month. Mean ST score was higher in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (both p = 0.001). Tear break-up time score showed a significant improvement in DE-NSS group, and it was lower in DE-NSS group than DE-SS group group at sixth and 12th months of the treatment (p = 0.044 and 0.027, respectively). Mean OSDI score was lower in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (p = 0.030 and 0.032, respectively). Conclusion: Topical CsA seems to be more effective in the treatment of the DE-NSS.falseCyclosporineDry eyeNon-sjogren’s syndromeSjogren’s syndromeCyclosporine | Dry eye | Non-sjogren’s syndrome | Sjogren’s syndromeJournal Article10.1007/s10792-021-01708-110.1007/s10792-021-01708-12-s2.0-85099760984WOS:0006110763000033348438414791485411573-2630